The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

被引:0
作者
Ouyang, Min [1 ]
Sun, Hanquan [2 ]
Liu, Xiaoyu [9 ]
Wu, Haijun [3 ]
Deng, Feilong [4 ]
Shen, Erdong [5 ]
Peng, Guozheng [6 ]
Wu, Hanbing [7 ]
Zhao, Yinshan [8 ]
Xiong, Hui [2 ]
Liu, Bin [2 ]
He, Shasha [2 ]
Hu, Ying [2 ]
Liu, Ping [2 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Gerontol, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China
[4] Liling Tradit Chinese Med Hosp, Dept Oncol, Liling, Peoples R China
[5] Yueyang Cent Hosp, Dept Oncol, Yueyang, Peoples R China
[6] Hengyang Cent Hosp, Dept Oncol, Hengyang, Peoples R China
[7] Hunan Univ Med Gen Hosp, Dept Oncol, Changsha, Peoples R China
[8] Fifth Peoples Hosp Huaihua, Dept Oncol, Huaihua, Peoples R China
[9] Loudi City Cent Hosp, Dept Oncol, Loudi, Peoples R China
关键词
Recurrent/Metastatic Head and Neck squamous cell carcinoma; Immunotherapy; Chemotherapy; Prognostic analysis; Real-world study; METASTATIC HEAD; DOCETAXEL; RECURRENT;
D O I
10.1186/s12957-024-03644-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThis study aims to elucidate the therapeutic efficacy and safety of a taxane-based chemotherapy in combination with immune checkpoint inhibitors regimen in patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).MethodsWe retrospectively collected clinical data from 154 patients who received at least two cycles of PD-1 inhibitors in combination with a taxane-based chemotherapy as first-line treatment in seven hospitals in Hunan Province, between December 2018 and December 2023. These patients were subjected to long-term follow-up.ResultsThe study included 154 eligible patients, with a median follow-up period of 21.5 months. The median PFS was 8.7 months, while the median OS was 16.7 months. The 12-month PFS rate was 43.6%, and the 12-month OS rate was 60.1%. At 24 months, the PFS rate was 34.4%, and the OS rate was 36.9%. With 26 complete responses (16.9%) and 52 partial responses (33.8%), the ORR was 50.6%. Stable disease was observed in 54 patients (35.1%), resulting in a disease control rate of 85.7%, while 22 patients showed progressive disease. In the univariate analysis, the distant organ metastasis had a statistically significant impact on both PFS and OS. Subsequent radiotherapy following this protocol also showed a statistically significant effect on PFS and OS. However, radiotherapy before recurrent metastasis did not significantly affect PFS, though it did have a significant impact on OS. Other factors analyzed did not show a statistically significant effect on PFS and OS. Multivariate analysis indicated that the distant organ metastasis and subsequent radiotherapy following this protocol were independent prognostic factors for PFS in patients with R/M HNSCC, and the latter was also an independent prognostic factor for OS in these patients. Regarding safety, during treatment anemia was observed in 97 patients, leukopenia in 64, neutropenia in 33, thrombocytopenia in 28, transaminase elevation in 46, hypothyroidism in 46 patients, and one patient stopped taking the medication due to a serious adverse reaction. No treatment-related deaths occurred.ConclusionThe combination of PD-1 inhibitors with a a taxane-based chemotherapy regimen as a first-line treatment for R/M HNSCC patients demonstrates good therapeutic efficacy and acceptable safety profiles.
引用
收藏
页数:13
相关论文
共 33 条
[1]   Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].
Bagchi, Sreya ;
Yuan, Robert ;
Engleman, Edgar G. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249
[2]  
BERNSTEIN T, 1977, NEW ENGL J MED, V297, P337
[3]   Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma [J].
Black, Christopher M. ;
Zheng, Dandan ;
Hair, Gleicy M. ;
Ai, Lei ;
Wang, Liya ;
Goto, Daisuke ;
Lerman, Nati ;
Bidadi, Behzad ;
Hanna, Glenn J. .
FRONTIERS IN ONCOLOGY, 2024, 14
[4]   5-Fluorouracil-induced acute coronary syndrome [J].
Das, Souvik K. ;
Das, Avik K. ;
William, Maged .
MEDICAL JOURNAL OF AUSTRALIA, 2019, 211 (06) :255-+
[5]   Long-term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status [J].
Du, Eugenie ;
Mazul, Angela L. ;
Farquhar, Doug ;
Brennan, Paul ;
Anantharaman, Devasena ;
Abedi-Ardekani, Behnoush ;
Weissler, Mark C. ;
Hayes, David N. ;
Olshan, Andrew F. ;
Zevallos, Jose P. .
LARYNGOSCOPE, 2019, 129 (11) :2506-2513
[6]   Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study [J].
Dzienis, M. R. ;
Cundom, J. E. ;
Fuentes, C. S. ;
Hansen, A. R. ;
Nordlinger, M. J. ;
Pastor, A. V. ;
Oppelt, P. ;
Neki, A. ;
Gregg, R. W. ;
Lima, I. P. F. ;
Franke, F. A. ;
Da Cunha Junior, G. F. ;
Tseng, J. E. ;
Loree, T. ;
Joshi, A. J. ;
Mccarthy, J. S. ;
Naicker, N. ;
Sidi, Y. ;
Gumuscu, B. ;
De Castro, G., Jr. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S839-S840
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study [J].
Falco, Agustin ;
Leiva, Mariano ;
Blanco, Albano ;
Cefarelli, Guido ;
Rodriguez, Andres ;
Melo, Juan ;
Cayol, Federico ;
Rizzo, Manglio Miguel ;
Sola, Alejandro ;
Rodriguez Montani, Hernan ;
Chacon, Matias ;
Enrico, Diego ;
Waisberg, Federico .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (02) :147-158
[9]   Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer [J].
Fuchs, Hannah ;
Pammer, Johannes ;
Minichsdorfer, Christoph ;
Posch, Doris ;
Kornek, Gabriela ;
Aretin, Marie-Bernadette ;
Fuereder, Thorsten .
MEDICAL ONCOLOGY, 2018, 35 (03)
[10]   Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study [J].
Fuereder, Thorsten ;
Minichsdorfer, Christoph ;
Mittlboeck, Martina ;
Wagner, Christina ;
Heller, Gerwin ;
Putz, Eva M. ;
Oberndorfer, Felicitas ;
Mullauer, Leonhard ;
Aretin, Marie-Bernadette ;
Czerny, Christian ;
Schwarz-Nemec, Ursula .
ORAL ONCOLOGY, 2022, 124